These 10 medicines are the best sellers!

On the other hand, in the fifth batch of centralized procurement of drugs to be carried out in June 2021, Hengrui's iodixanol bid failed, and the market was empty.
It is expected that after the centralized procurement, the domestic iodixanol market will usher in a major reshuffle
.
Compared with the drug transaction situation in Henan Province in the first half of 2021, Hengrui's iodixanol infusion has dropped from third to seventh, which may be related to the failure of the fifth batch of national harvests
.
According to data from Minet.
com, in 2019, the sales of terminal iodixanol injection in Chinese public medical institutions exceeded 3.
5 billion yuan
.
Hengrui's iodixanol accounted for 50.
48% of the market share
.
Under centralized procurement, it is also a question whether half of the market share can be maintained
.

02The supply rate is "ice and fire", Haisco and Yichang people are blessed.
.
.

At present, six rounds of drug procurement by the state have been carried out, and the seventh round of centralized procurement is also starting to report the volume
.
Up to now, the first five batches have been implemented successively, and the price reduction of medicines is between 48% and 59%
.

It is understood that on April 30, 2021, the results of the fourth batch of national centralized drug procurement were fully implemented in Henan Province
.
A total of 45 drugs were selected this time, involving hypertension, diabetes, digestive tract diseases, mental diseases, tumors and other therapeutic fields; on October 1, 2021, the fifth batch of centralized procurement was implemented in Henan Province
.
The Henan Provincial Medical Insurance Bureau requires that four products, including gemcitabine hydrochloride for injection, lansoprazole for injection, palonosetron hydrochloride injection, and medium/long-chain fat emulsion injection (C8-24Ve), continue to implement provincial regulations.
After the acquisition of the results, the national centralized procurement results will be implemented from March 1, 2022 after the expiration of the provincial centralized procurement agreement
.

Judging from the supply of selected drugs in Henan Province's 2021 national centralized procurement, the variety with a supply rate of 100% is emtricitabine/tenofovir oral normal-release dosage form
.
In the fourth batch of centralized procurement bidding, the price of Emtricitabine and Tenofovir Tablets just reviewed by Haisco was 22 yuan, which was 65% lower than the highest effective declared price, and successfully squeezed out the original research pharmaceutical company Gilead
.

The variety was finally won by Anhui Baker Biology, Haisco, and Chia Tai Tianqing.
Among them, Haisco's emtricitabine and tenofovir tablets were supplied to Henan Province
.

The least supply rate is clindamycin oral normal release dosage form, only 50.
28%
.
In the second batch of centralized procurement, the variety was won by Harbin Zhenbao Pharmaceutical, Yichang Renfu, Chongqing Yaoyou, and Sichuan Kelun.
Among them, Yichang Renfu was supplied to Henan Province
.
According to the second batch of centralized procurement rules, the actual selected enterprises in the country are 4 or more varieties, and the procurement cycle of this round is 3 years in principle
.
Henan Province will fully implement the second batch of centralized collection results before April 30, 2020.
It can be seen that Yichang Renfu's clindamycin needs to be supplied to Henan Province for at least one year
.

From other perspectives, there are 153 varieties with a supply rate of 90-99.
99%; 40 varieties with a supply rate of 80%; 10 varieties with a supply rate of 70%, and oral acarbose is distributed.
There are 3 varieties with a supply rate of about 60%, namely azithromycin injection, duloxetine oral normal-release formulation, and acetaminophen oral normal-release formulation
.

According to the rules of the first five batches of centralized procurement, except for a few varieties, the agreed procurement volume for most varieties in the first year of each variety is - if there are 1, 2, 3, 4 or more companies actually selected in the country, it will be the first year 50%, 60%, 70%, 80% of the calculation base of the agreed purchase volume
.
In this way, the supply rate of some varieties is not up to the standard
.

Henan Province also pointed out the possible reasons under this notice, "some drug production and operation enterprises did not respond to the purchase orders of medical institutions in a timely manner, and the drug supply rate was low" and "in the implementation of the national drug centralized procurement policy, some drugs The institution did not return the payment in time as required; the supply rate of selected drugs by individual enterprises was low
.
”

In addition, among the top 100 production enterprises in Henan Province in terms of online supply in 2021, the top ten are Hengrui (supply amount of 1.
660 billion yuan), Chia Tai Tianqing (supply amount of 1.
425 billion yuan), and AstraZeneca (supply amount of 1.
425 billion yuan) Amount of 899 million yuan), Qilu Pharmaceutical (872 million yuan), Shanghai Roche (supply amount of 598 million yuan), Hangzhou Zhongmei Huadong (supply amount of 541 million yuan), Jiangsu Changjiang Pharmaceutical (supply amount of 523 million yuan) , Bayer (supply amount of 480 million yuan), Chengdu Bite (supply amount of 479 million yuan), Shijiazhuang Siyao (supply amount of 472 million yuan)
.

Appendix:

1.
Online transactions in cities and counties directly under the jurisdiction of each province in 2021.
pdf

2.
The top 50 pharmaceutical institutions by online purchase amount in 2021.
pdf

3.
Top 100 Manufacturers in Online Supply Amount in 2021.
pdf

4.
Top 50 operating companies by online delivery value in 2021.
pdf

5.
Procurement of selected drugs in national centralized procurement with volume in 2021.
pdf

6.
Supply of selected drugs in national centralized procurement with volume in 2021.
pdf